A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma



Status:Recruiting
Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 30
Updated:3/10/2019
Start Date:July 1, 2016
End Date:March 1, 2024
Contact:Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:
Email:JNJ.CT@sylogent.com

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric
participants is consistent with that in adults (part 1) and to assess efficacy (event-free
survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and
etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI)
background therapy compared to RICE or RVICI background therapy alone (part 2).

This is a Phase 3, randomized (study medication assigned to participants by chance),
open-label (identity of study drug will be known to participant and study staff), controlled
study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in
part, which will be conducted before starting the randomized part (Part 2) of the study and
Part 2 is a randomized and open-label study. Part 1 and Part 2 of the study will be conducted
in 3 phases: a Pretreatment (Screening) Phase (Up to 14 days before administration of study
drug), a Treatment Phase, and a Posttreatment Phase. The Treatment Phase will extend from
enrollment (in Part 1) or randomization (in Part 2) until 1 of the following: 1) completion
of 3 cycles of therapy, 2) transplantation, if clinically indicated, or 3) progressive
disease (PD), whichever comes first. The Posttreatment Phase will continue until death, loss
to follow up, consent withdrawal, or study end, whichever occurs first. The end of study is
defined as when approximately 60 event-free survival (EFS) events have occurred in Part 2
(death, disease progression, or lack of complete response [CR] or partial response [PR] after
3 cycles of treatment based on blinded independent event review), or the sponsor terminates
the study, whichever comes first. Participants in Part 1 will be 1 to less than (<) 18 years
old. Participants in Part 2 will be 1 to 30 years old. Participants will be primarily
evaluated for pharmacokinetics in part 1 and efficacy (EFS) of ibrutinib in combination with
RICE or RVICI background therapy compared to RICE or RVICI background therapy alone in part
2. Participants' safety will be monitored throughout the study.

Inclusion Criteria:

- Participants with 1 to less than (<) 18 years of age (Part 1 only), or 1 to 30 years
of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL)
occurred at <18 years of age (Part 2 only)

- Participants must be in first recurrence or have disease that is primarily refractory
to conventional therapy

- Participants must have at least 1 of the following: 1 site of measurable disease
greater than (>) 1 centimeter (cm) in the longest diameter and >1 cm in the shortest
diameter by radiological imaging; bone marrow involvement; cerebrospinal fluid with
blasts present

- Participants with lansky-Karnofsky score of greater than or equal to (>=) 50

- Adolescent women/young women of childbearing potential must have a negative highly
sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test
at Screening before enrollment/randomization. Adolescent/young women who are pregnant
or breastfeeding are ineligible for this study

Exclusion Criteria:

- Participants with ongoing anticoagulation treatment with warfarin or equivalent
vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known
to be strong CYP3A4/5 inhibitors, or has taken any disallowed therapies as noted in
Section 8.2, Prohibited Medications, before the planned first dose of study drug

- Participants with inherited or acquired bleeding disorders

- Participants with clinically significant arrhythmias, complex congenital heart
disease, or left ventricular ejection fraction (LVEF) <50 percent (%) or shortening
fraction (SF) <=28%

- Participants with known history of human immunodeficiency virus (HIV) or active
Hepatitis B or C virus

- Participants with any condition that could interfere with the absorption or metabolism
of ibrutinib including malabsorption syndrome, disease significantly affecting
gastrointestinal function, or resection of the stomach or small bowel

- Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or
its excipients (refer to Investigator's Brochure)

- A diagnosis of post-transplant lymphoproliferative disease (PTLD)

- Participants who are within 6 months of an allogeneic bone marrow transplant

- Participants who have had prior exposure to ibrutinib
We found this trial at
23
sites
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1001 Johnson Ferry Road Northeast
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
15 Jean Joseph Crocqlaan
Brussel, 1020
?
mi
from
Brussel,
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Salt Lake City, Utah 84143
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
40 Sunshine Cottage Road
Valhalla, New York 10595
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials